Rapalogs and mTOR inhibitors as anti-aging therapeutics
Open accessThe DOI matches its Crossref record; 133 of the 133 references it cites were found in a registry or an index.
Abstract
Rapamycin, an inhibitor of mechanistic target of rapamycin (mTOR), has the strongest experimental support to date as a potential anti-aging therapeutic in mammals. Unlike many other compounds that have been claimed to influence longevity, rapamycin has been repeatedly tested in long-lived, genetically heterogeneous mice, in which it extends both mean and maximum life spans. However, the mechanism that accounts for these effects is far from clear, and a growing list of side effects make it doubtful that rapamycin would ultimately be beneficial in humans. This Review discusses the prospects for developing newer, safer anti-aging therapies based on analogs of rapamycin (termed rapalogs) or other approaches targeting mTOR signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rapamycin and its analogs (so-called ‘rapalogs’) suppress the SASP by inhibiting mTOR and appear to extend healthspan and lifespan in mice105,108,109.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [105]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In fact, reviewing the effects of other interventions like rapalogs and sirtuins also shows that they may be impacting many of the similar hallmarks of aging (Lamming et al. 2013, Grabowska et al. 2017).”
From Benefits of Metformin in Attenuating the Hallmarks of Aging (2020) · cites this paper as Lamming et al. 2013
The cited source says what the claim attributes to it.
In the citing paper
“Many of the side effects of rapamycin, which include immunosuppression, hyperlipidemia and hyperglycemia, have raised concerns about the feasibility of using rapamycin to promote healthy longevity in humans and slowed clinical evaluation of mTOR inhibitors for diseases of aging 26.”
From Targeting the biology of aging with mTOR inhibitors (2023) · cites this paper as [26]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“SASP inhibitors (senomorphics) can directly or indirectly attenuate the SASP of senescent cells by inhibiting transcription factor nuclear factor (NF)-κB, the JAK-STAT signal transduction pathway, the serine/threonine protein kinase mTOR, mitochondrial complex-1-related or 4-related targets, or other pathways involved in the induction and maintenance of the SASP103–106.”
From Cellular senescence and senolytics: the path to the clinic (2022) · cites this paper as [105]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“no senolytic compounds developed to date are able to eliminate all types of senescent cells; further they retain a low level of toxicity to young normal cells (Lamming et al., 2013).”
From Single senescent cell sequencing reveals heterogeneity in senescent cells induced by telomere erosion (2019) · cites this paper as Lamming et al., 2013
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1
Kim, J., Kundu, M., Viollet, B., & Guan, K.-L. (2011) · Nature Cell Biology · doi:10.1038/ncb2152 · Cited by 7,227 · cited 2×
“the autophagy-initiating kinase ULK1 (46).”
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 14×
“We might therefore expect other compounds that activate AMPK to specifically inhibit mTORC1 activity.”
BackgroundInfluentialAMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849 · cited 1×
“phorylation of TSC2 and the inhibitory phosphorylation of raptor, an essential component of mTORC1 (92, 93).”
BackgroundNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766
Sancak, Y., Bar-Peled, L., Zoncu, R., Markhard, A. L., Nada, S., & Sabatini, D. M. (2010) · Cell · doi:10.1016/j.cell.2010.02.024 · Cited by 2,464 · cited 1×
“The Rag proteins activate mTORC1 by localizing mTORC1 to the lysosome via interaction with the ragulator complex (110).”
BackgroundSelf-citationProlonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365 · cited 1×
“This effect was first observed in certain cultured cell lines (73), and we have recently shown that it also occurs in vivo in multiple tissues including liver, muscle, and adipose (see Figure 2).”
BackgroundSelf-citationLaplante, M., & Sabatini, D. M. (2009) · Journal of Cell Science · doi:10.1242/jcs.051011 · Cited by 2,170 · cited 1×
“through a wide variety of signaling mechanisms and have roles in many aspects of physiology, which have been reviewed in depth (9).”
BackgroundSelf-citationFranceschi, C., Capri, M., Monti, D., Giunta, S., Olivieri, F., Sevini, F., Panourgia, M. P., Invidia, L., Celani, L., Scurti, M., et al. (2007) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2006.11.016 · Cited by 2,087 · cited 1×
“Chronic, low-grade inflammation is a feature of aging, and almost every chronic disease has an inflammatory component (71).”
BackgroundA mammalian protein targeted by G1-arresting rapamycin–receptor complex
Brown, E. J., Albers, M. W., Bum Shin, T., ichikawa, K., Keith, C. T., Lane, W. S., & Schreiber, S. L. (1994) · Nature · doi:10.1038/369756a0 · Cited by 2,053 · cited 2×
“Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer.”
Background
Cited by
Items 101–200 of 565
Intrinsic Age-Dependent Changes and Cell-Cell Contacts Regulate Nephron Progenitor Lifespan
Chen, S., Brunskill, E. W., Potter, S. S., Dexheimer, P. J., Salomonis, N., Aronow, B. J., Hong, C. I., Zhang, T., & Kopan, R. (2015) · Developmental Cell · doi:10.1016/j.devcel.2015.09.009 · Cited by 102
Less is more: improving proteostasis by translation slow down
Sherman, M. Y., & Qian, S. (2013) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.09.003 · Cited by 102
Altman, J. K., Szilard, A., Goussetis, D. J., Sassano, A., Colamonici, M., Gounaris, E. G., Frankfurt, O., Giles, F. J., Eklund, E. A., Beauchamp, E. M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3218 · Cited by 102
“There is emerging evidence that inhibition of both mTORC1 and mTORC2 complexes by catalytic targeting of mTOR may provide a powerful approach for the treatment of malignancies (1–5) and aging-related pathologies (6, 7).”
BackgroundHouédé, N., & Pourquier, P. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.06.004 · Cited by 97
Yang, J., Zhou, X., Fan, X., Xiao, M., Yang, D., Liang, B., Dai, M., Shan, L., Lu, J., Lin, Z., et al. (2016) · Blood · doi:10.1182/blood-2015-10-672964 · Cited by 91
“Recent studies have established mTORC1 as a key modulator of aging and age-related diseases.(19,20) Inhibition of the mTORC1 pathway has been shown to extend the life span of model organisms and confer protection against some age-related pathologies.”
BackgroundThe Role of Rapamycin in Healthspan Extension via the Delay of Organ Aging
Zhang, Y., Zhang, J., & Wang, S. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101376 · Cited by 92
Interventions for age-related diseases: Shifting the paradigm
Figueira, I., Fernandes, A., Mladenovic Djordjevic, A., Lopez-Contreras, A., Henriques, C. M., Selman, C., Ferreiro, E., Gonos, E. S., Trejo, J. L., Misra, J., et al. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.09.009 · Cited by 87
Emerging role of metabolic signaling in synovial joint remodeling and osteoarthritis
June, R. K., Liu‐Bryan, R., Long, F., & Griffin, T. M. (2016) · Journal of Orthopaedic Research® · doi:10.1002/jor.23420 · Cited by 93
“The impact of this metabolic renaissance is evident in multiple related areas of investigation, including epigenetics, regenerative medicine, immunology, and experimental therapeutics [20-23].”
Regan, J. C., Lu, Y., Ureña, E., Meilenbrock, R. L., Catterson, J. H., Kißler, D., Fröhlich, J., Funk, E., & Partridge, L. (2022) · Nature Aging · doi:10.1038/s43587-022-00308-7 · Cited by 103
“…(IIS)/mTOR, and targeting these pathways directly offers a more translational route for anti-aging therapy than do chronic dietary regimens 18–21 . mTOR is a highly conserved signaling hub that integrates multiple cues to regulate key cellular functions, including cell growth, division,…”
Lysosomes: regulators of autophagy in the retinal pigmented epithelium
Sinha, D., Valapala, M., Shang, P., Hose, S., Grebe, R., Lutty, G. A., Zigler, J. S., Kaarniranta, K., & Handa, J. T. (2016) · Experimental Eye Research · doi:10.1016/j.exer.2015.08.018 · Cited by 88
“While rapamycin or rapalogs (Lamming et al., 2013) have shown therapeutic efficacy for agerelated pathologies in animal models, significant side effects limit their use in humans.”
BackgroundDrug repurposing for the treatment of glioblastoma multiforme
Abbruzzese, C., Matteoni, S., Signore, M., Cardone, L., Nath, K., Glickson, J. D., & Paggi, M. G. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0642-x · Cited by 86
“cellular ageing, [61, 62] and are also employed in Phase 2 clinical trials involving GBM patients showing therapeutic benefits in subjects whose tumor displays high mTORC1 activity [63].”
BackgroundTransmembrane 4 L Six Family Member 5 Senses Arginine for mTORC1 Signaling
Jung, J. W., Macalino, S. J. Y., Cui, M., Kim, J. E., Kim, H.-J., Song, D.-G., Nam, S. H., Kim, S., Choi, S., & Lee, J. W. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.03.005 · Cited by 82
Metformin: A Potential Candidate for Targeting Aging Mechanisms
Hu, D., Xie, F., Xiao, Y., Chen, L., Zhong, J., Huang, D., Chen, J., Wei, J., Jiang, Y., & Zhong, T. (2021) · Aging and Disease · doi:10.14336/ad.2020.0702 · Cited by 88
“metformin [10], rapamycin [11], resveratrol [12], spermidine [13], curcumin [14] and astaxanthin [15], have suggested that while the aging process, cannot be rewired, Volume 12, Number 2; 480-493, April 2021”
BackgroundRapamycin Blocks Induction of the Thermogenic Program in White Adipose Tissue
Tran, C. M., Mukherjee, S., Ye, L., Frederick, D. W., Kissig, M., Davis, J. G., Lamming, D. W., Seale, P., & Baur, J. A. (2016) · Diabetes · doi:10.2337/db15-0502 · Cited by 82
“Rapamycin extends life span in model organisms ranging from yeast to mice; however, its potential utility in humans remains hampered by side effects, including alterations in glucose and lipid metabolism (1).”
BackgroundSelf-citationMetabolic Communication and Healthy Aging: Where Should We Focus Our Energy?
Smith, H. J., Sharma, A., & Mair, W. B. (2020) · Developmental Cell · doi:10.1016/j.devcel.2020.06.011 · Cited by 84
Tassone, F., Protic, D. D., Allen, E. G., Archibald, A. D., Baud, A., Brown, T. W., Budimirovic, D. B., Cohen, J., Dufour, B. D., Eiges, R., et al. (2023) · Cells · doi:10.3390/cells12182330 · Cited by 84
Novel compounds for the modulation of mTOR and autophagy to treat neurodegenerative diseases
Heras-Sandoval, D., Pérez-Rojas, J. M., & Pedraza-Chaverri, J. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109442 · Cited by 80
Translating the Science of Aging into Therapeutic Interventions
Kirkland, J. L. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a025908 · Cited by 78
“These include rapamycin, drugs related to rapamycin (rapalogs), metformin, 17 a-estradiol, angiotensin converting enzyme inhibitors (and possibly angiotensin receptor blockers), flavonoids related to resveratrol, and aspirin and salsalate (Ferder et al. 1993; Linz et al. 1997, 2000; Basso et al. 2007; Anisimov et al.…”
BackgroundMitochondrial function and mitochondrial DNA maintenance with advancing age
Gaziev, A. I., Abdullaev, S., & Podlutsky, A. (2014) · Biogerontology · doi:10.1007/s10522-014-9515-2 · Cited by 77
“Various age-related neurodegenerative disorders are associated with accumulation of dysfunctional mitochondria (Ravikumar et al. 2010; Lamming et al. 2013).”
BackgroundTherapeutic targeting of senescent cells in the CNS
Riessland, M., Ximerakis, M., Jarjour, A. A., Zhang, B., & Orr, M. E. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01033-z · Cited by 77
Control of B lymphocyte development and functions by the mTOR signaling pathways
Iwata, T., Ramírez, J. A., Park, H., & Iritani, B. M. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.04.005 · Cited by 80
Improving retinal mitochondrial function as a treatment for age-related macular degeneration
Ebeling, M. C., Polanco, J. R., Qu, J., Tu, C., Montezuma, S. R., & Ferrington, D. A. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101552 · Cited by 74
“However, it may be worthwhile to take a second look at this drug or some of the newly developed “rapalogs” [6,30] to see if more M.”
BackgroundYamamoto‐Imoto, H., Minami, S., Shioda, T., Yamashita, Y., Sakai, S., Maeda, S., Yamamoto, T., Oki, S., Takashima, M., Yamamuro, T., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110444 · Cited by 80
The role of the TOR pathway in mediating the link between nutrition and longevity
Lushchak, O., Strilbytska, O., Piskovatska, V., Storey, K. B., Koliada, A., & Vaiserman, A. (2017) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2017.03.005 · Cited by 73
Myelin lipid metabolism and its role in myelination and myelin maintenance
Barnes-Vélez, J. A., Aksoy Yasar, F. B., & Hu, J. (2023) · The Innovation · doi:10.1016/j.xinn.2022.100360 · Cited by 73
Genetic variants near MLST8 and DHX57 affect the epigenetic age of the cerebellum
Lu, A. T., Hannon, E., Levine, M. E., Hao, K., Crimmins, E. M., Lunnon, K., Kozlenkov, A., Mill, J., Dracheva, S., & Horvath, S. (2016) · Nature Communications · doi:10.1038/ncomms10561 · Cited by 71
Diminished mTOR signaling: a common mode of action for endocrine longevity factors
Lamming, D. W. (2014) · SpringerPlus · doi:10.1186/2193-1801-3-735 · Cited by 71
“From the standpoint of glucose homeostasis and insulin sensitivity, rapamycin and CR have quite divergent effects, with rapamycin treatment resulting in glucose intolerance and hepatic insulin resistance (Lamming et al. 2012, 2013a).”
Self-citationLi, G., & Zhao, Y. (2024) · Horticulture Research · doi:10.1093/hr/uhae099 · Cited by 71
“The TOR protein is formed by five domains, comprising HEAT (Huntington, EF3A, ATM, TOR) repeats, FAT (Focal adhesion target), FRB (FKBR12 and rapamycin binding), kinase, and FATC (C-terminal of FAT) [54, 59–61].”
BackgroundSubramanian, A., Tamilanban, T., Alsayari, A., Ramachawolran, G., Wong, L. S., Sekar, M., Gan, S. H., Subramaniyan, V., Chinni, S. V., Rani, N. N. I. M., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1094351 · Cited by 73
“The rapalogs and rapamycin act as autophagy inducers by stabilizing raptor-mTOR connectivity and inhibiting mTOR stimulation (Lamming et al., 2013).”
BackgroundSilymarin Suppresses Cellular Inflammation By Inducing Reparative Stress Signaling
Lovelace, E. S., Wagoner, J., MacDonald, J., Bammler, T. K., Bruckner, J. J., Brownell, J., Beyer, R. P., Zink, E., Kim, Y., Kyle, J. E., et al. (2015) · Journal of Natural Products · doi:10.1021/acs.jnatprod.5b00288 · Cited by 73
Lamming, D. W., Cummings, N. E., Rastelli, A. L., Gao, F., Cava, E., Bertozzi, B., Spelta, F., Pili, R., & Fontana, L. (2015) · Oncotarget · doi:10.18632/oncotarget.5180 · Cited by 69
“Unfortunately, the potentially serious side effects of rapamycin and rapamycin analogs in humans may preclude the use of these compounds to prevent or delay age-related diseases [15, 16].”
Self-citationCalorie Restriction Mimetics: Upstream-Type Compounds for Modulating Glucose Metabolism
Shintani, H., Shintani, T., Ashida, H., & Sato, M. (2018) · Nutrients · doi:10.3390/nu10121821 · Cited by 70
“Rapamycin exerts substantial regulatory effects on important biological processes such as proliferation and inflammation [30].”
BackgroundAntiaging effects of dietary supplements and natural products
Gao, L., Liu, X., Luo, X., Lou, X., Li, P., Li, X., & Liu, X. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1192714 · Cited by 71
“mTOR signaling is closely related to the aging processes in various organisms such as yeasts, worms, flies, and mammals (Lamming et al., 2013; Zheng et al., 2021).”
BackgroundThe mammalian target of rapamycin at the crossroad between cognitive aging and Alzheimer’s disease
Talboom, J. S., Velazquez, R., & Oddo, S. (2015) · npj Aging and Mechanisms of Disease · doi:10.1038/npjamd.2015.8 · Cited by 67
Cassano, T., Magini, A., Giovagnoli, S., Polchi, A., Calcagnini, S., Pace, L., Lavecchia, M. A., Scuderi, C., Bronzuoli, M. R., Ruggeri, L., et al. (2019) · Experimental Neurology · doi:10.1016/j.expneurol.2018.09.011 · Cited by 66
Telomere Dysfunction and Cell Senescence in Chronic Lung Diseases: Therapeutic Potential
Adnot, S., Amsellem, V., Boyer, L., Marcos, É., Saker, M., Houssaini, A., Kebe, K., Dagouassat, M., Lipskaia, L., & Boczkowski, J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.06.007 · Cited by 72
Rapamycin-induced metabolic defects are reversible in both lean and obese mice
Liu, Y., Diaz, V., Fernandez, E., Strong, R., Ye, L., Baur, J. A., Lamming, D. W., Richardson, A., & Salmon, A. B. (2014) · Aging · doi:10.18632/aging.100688 · Cited by 68
“It has been suggested that the negative side effects of rapamycin treatment, including impaired glucose metabolism, will limit the use of rapamycin for the treatment of age-related diseases [44].”
BackgroundSelf-citationmTOR Inhibitor Therapy and Metabolic Consequences: Where Do We Stand?
Kezić, A., Popović, L., & Lalic, K. S. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/2640342 · Cited by 72
“This assumption might be operating when mTOR inhibitors are used as antiaging therapeutics because mTORC1 inhibition would achieve the desired effects by avoiding metabolic disorders caused by mTORC2 inhibition [84].”
BackgroundKhalil, R., Diab‐Assaf, M., & Lemaître, J.-M. (2023) · Cells · doi:10.3390/cells12060915 · Cited by 74
Nutrients and Pathways that Regulate Health Span and Life Span
Pignatti, C., D’Adamo, S., Stefanelli, C., Flamigni, F., & Cetrullo, S. (2020) · Geriatrics · doi:10.3390/geriatrics5040095 · Cited by 65
“(1) The classical mTOR inhibitor, rapamycin and novel drugs as rapalogs, having the same molecular scaffold as rapamycin, but with different physiochemical properties [126].”
Backgroundde Cavanagh, E. M. V., Inserra, F., & Ferder, L. (2015) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00459.2014 · Cited by 70
Tang, B., Cai, J., Sun, L. N., Li, Y., Qu, J., Snider, B. J., & Wu, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103364 · Cited by 70
“3A, and 3B) or reducing endoplasmic reticulum quality-control system [28], low doses of LA or Epo, even autophagy enhancers, rapamycin and its analogs [29], would be better candidates to be used against oxidative injury in RPE cells.”
BackgroundNovel strategies for anti-aging drug discovery
Saraswat, K., & Rizvi, S. I. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1349750 · Cited by 66
“mTORC1 that plays a key role in de novo protein synthesis, autophagy, and cell growth is activated in presence of sufficient nutrients (amino acids, glucose, WNT ligands, oxygen, and insulin/IGF-1) that bind to and activate the PI3K/AKT and Ras/MAPK pathways as well as AMPK signaling which finally converge into the mT…”
BackgroundZhang, J., Zhao, P., Quan, N., Wang, L., Chen, X., Cates, C. A., Rousselle, T. V., & Li, J. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.08.034 · Cited by 66
“Genetic alterations of mTORC1 elements affect aging in mice [4].”
BackgroundSalminen, A. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02444-6 · Cited by 67
“Given that rapamycin has been able to extend the lifespan of rodents [167], the inhibitors of mTOR protein, such as rapalogs, have been claimed to be promising candidates for anti-aging therapeutics [178].”
BackgroundMulti-omic underpinnings of epigenetic aging and human longevity
Mavromatis, L. A., Rosoff, D. B., Bell, A. S., Jung, J., Wagner, J., & Lohoff, F. W. (2023) · Nature Communications · doi:10.1038/s41467-023-37729-w · Cited by 67
“For instance, SESN1 , a high con fi dence GrimAge gene, positively regulates lifespan in Caenorhabditis elegans 39 and inhibits the mammalian target of rapamycin protein (mTOR), a molecular process that has been widely investigated for its possible longevity bene fi ts 40 .”
Towards a therapy for mitochondrial disease: an update
Garone, C., & Viscomi, C. F. (2018) · Biochemical Society Transactions · doi:10.1042/bst20180134 · Cited by 68
Diabetes-accelerated experimental osteoarthritis is prevented by autophagy activation
Ribeiro, M. P., de Figueroa, P. L., Nogueira-Recalde, U., Centeno, A., Mendes, A. F., Blanco, F. J., & Caramés, B. (2016) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2016.06.019 · Cited by 63
Induced proximity-based therapeutic modalities
King, E. A., Meyers, M., & Nomura, D. K. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01316-z · Cited by 74
“2), improved the structure of rapamycin to make it more stable and better tolerated 18 .”
Romine, J., Gao, X., Xu, X., So, K., & Chen, J. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.01.003 · Cited by 63
mTOR controls kidney epithelia in health and disease
Grahammer, F., Wanner, N., & Huber, T. B. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft491 · Cited by 61
“For a comprehensive and detailed general overview of mTOR signalling cascades we refer to several recent reviews and review series [19–22].”
BackgroundAUTEN-67, an autophagy-enhancing drug candidate with potent antiaging and neuroprotective effects
Papp, D., Kovács, T., Billes, V., Varga, M., Tarnóci, A., Hackler, L., Puskás, L. G., Liliom, H., Tárnok, K., Schlett, K., et al. (2016) · Autophagy · doi:10.1080/15548627.2015.1082023 · Cited by 62
Health Benefits of Anti-aging Drugs
Piskovatska, V., Strilbytska, O. M., Koliada, A. K., Vaiserman, A. M., & Lushchak, O. V. (2019) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-981-13-3681-2_13 · Cited by 64
mTOR in health and in sickness
Liko, D., & Hall, M. N. (2015) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1326-7 · Cited by 63
“Since then, a number of rapamycin analogs (rapalogs) have been developed and are prescribed for use against specific types of tumors [121].”
Lawrence, M., Goyal, A., Pathak, S., & Ganguly, P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137411 · Cited by 63
“TORC1 forms a multiprotein complex with TORC2 and is regulated by mTOR [129].”
BackgroundMoore, M. N. (2015) · Environmental Research · doi:10.1016/j.envres.2015.03.015 · Cited by 68
“…Corradetti & Guan, 2006; Dan et al., 2008; de Souza et al., 2010; Deeb et al., 2007; Harries et al., 2012; Hau et al., 2013; Johnson et al., 2009; Lamming et al., 2013; Laplante & Sabatini, 2010, 2012, 2013; Lee et al., 2013; Madrid et al., 2001; Markman et al., 2010; Martin et al., 2012;…”
White, Z., White, R. B., McMahon, C., Grounds, M. D., & Shavlakadze, T. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.06.012 · Cited by 59
Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion
Chen, L., Xu, B., Liu, L., Liu, C., Luo, Y., Chen, X., Barzegar, M., Chung, J., & Huang, S. (2015) · Oncotarget · doi:10.18632/oncotarget.3044 · Cited by 72
“As predicted, PP242 inhibited both mTORC1-mediated phosphorylation of S6K1 and mTORC2-mediated phosphorylation of Akt in Rh30 and HT29 cells (Figure 4A).”
BackgroundMethodInfluentialAsl, M. H., Khelejani, F. P., Mahdavi, S. Z. B., Emrahi, L., Jebelli, A., & Mokhtarzadeh, A. (2022) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30221 · Cited by 61
“Although mTOR inhibitors or paralogs, a family of drugs that suppress cell proliferation through inhibiting the mTOR pathway, have been broadly used in clinical cancer treatment trials over the years, these agents alone cannot elevate GAS5 expression in the cell.(56,141) However, combined with P13K inhibitors, dual mT…”
BackgroundTranslating the Biology of Aging into New Therapeutics for Alzheimer's Disease: Senolytics
Riessland, M., & Orr, M. E. (2023) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2023.104 · Cited by 52
“…to interact either with NF-κ B and C/EBP β transcriptional activities at different levels have been developed (summarized in: 81). mTOR inhibition— Rapamycin is a well-studied FDA approved immunosuppressive drug that has been shown to extend lifespan in yeast, worms, flies, and mice (83, 84).”
BackgroundVascular Ageing: Mechanisms, Risk Factors, and Treatment Strategies
Ya, J., & Bayraktutan, U. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411538 · Cited by 57
Harputlugil, E., Hine, C., Vargas, D., Robertson, L., Manning, B. D., & Mitchell, J. R. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.07.018 · Cited by 57
“In our model, rapamycin not only failed to recapitulate benefits of PR but also partially abrogated PR benefits, possibly due to its aforementioned negative effects on insulin signaling via mTORC2 inhibition (Lamming et al., 2013).”
Ye, L., Widlund, A. L., Sims, C. A., Lamming, D. W., Guan, Y., Davis, J. G., Sabatini, D. M., Harrison, D. E., Vang, O., & Baur, J. A. (2013) · Aging · doi:10.18632/aging.100576 · Cited by 54
Self-citationHarrison, D. E., Strong, R., Reifsnyder, P., Rosenthal, N., Korstanje, R., Fernandez, E., Flurkey, K., Ginsburg, B. C., Murrell, M. D., Javors, M. A., et al. (2023) · GeroScience · doi:10.1007/s11357-023-01011-0 · Cited by 56
Hoffmann, J. M., & Partridge, L. (2015) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2015.1067186 · Cited by 61
“The aging process has proved to be malleable to genetic, dietary and pharmacological interventions (Fontana & Partridge, 2015; Fontana et al., 2010; Kenyon, 2010; Lamming et al., 2013).”
BackgroundJahrling, J., & Laberge, R.-M. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150610125856 · Cited by 53
“This effect appears to be due to a disruption of mTORC2 [30] as long term rapamycin treatment leads to mTORC2 inhibition in culture and in vivo [30, 89].”
BackgroundFunctional analyses of major cancer-related signaling pathways in Alzheimer's disease etiology
Guo, J., Cheng, J., North, B. J., & Wei, W. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.07.001 · Cited by 55
Growth factor, energy and nutrient sensing signalling pathways in metabolic ageing
Bettedi, L., & Foukas, L. C. (2017) · Biogerontology · doi:10.1007/s10522-017-9724-6 · Cited by 53
“Genetic or pharmacological inhibition of mTOR signalling has been found to extend the lifespan of invertebrate species including yeast, nematodes, fruit flies and mice (Kapahi et al. 2010; Lamming et al. 2013).”
BackgroundTargeting Autophagy with Natural Products as a Potential Therapeutic Approach for Cancer
Al‐Bari, M. A. A., Ito, Y., Ahmed, S. B. M., Radwan, N., Ahmed, H. S., & Eid, N. A. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189807 · Cited by 59
Energetic interventions for healthspan and resiliency with aging
Huffman, D. M., Schafer, M. J., & LeBrasseur, N. K. (2016) · Experimental Gerontology · doi:10.1016/j.exger.2016.05.012 · Cited by 54
Unraveling the message: insights into comparative genomics of the naked mole-rat
Lewis, K. N., Soifer, I., Melamud, E., Roy, M. A., McIsaac, R. S., Hibbs, M., & Buffenstein, R. (2016) · Mammalian Genome · doi:10.1007/s00335-016-9648-5 · Cited by 61
“The insulin and mTOR pathways are considered key players in mouse and human aging, with downregulation in these pathways and/or altered signaling through mutations of receptors linked to increased longevity (Selman et al. 2008; Selman and Withers 2011; Lamming and Sabatini 2011; Johnson et al. 2013; Lamming et al. 201…”
BackgroundMitochondria-targeted senotherapeutic interventions
Atayik, M. C., & Çakatay, U. (2022) · Biogerontology · doi:10.1007/s10522-022-09973-y · Cited by 54
Inflammaging, cellular senescence, and cognitive aging after traumatic brain injury
Lu, Y., Jarrahi, A., Moore, N. D., Bartoli, M., Brann, D. W., Baban, B., & Dhandapani, K. M. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106090 · Cited by 54
“…sirtuin activators, mTOR activators, antioxidants, autophagy activators, and proteasome activators (Hubbard and Sinclair, 2014; Wei et al., 2017; Lamming et al., 2013; Chondrogianni et al., 2015; Tilstra et al., 2012; Xu et al., 2015b; Kang et al., 2017; Cao et al., 2011; Lee et al., 2016).”
BackgroundRobust LC3B lipidation analysis by precisely adjusting autophagic flux
Liebl, M. P., Meister, S. C., Frey, L., Hendrich, K., Klemmer, A., Wohlfart, B., Untucht, C., Nuber, J., Pohl, C., & Lakics, V. (2022) · Scientific Reports · doi:10.1038/s41598-021-03875-8 · Cited by 53
Filippone, S. M., Samidurai, A., Roh, S. K., Cain, C. K., He, J., Salloum, F. N., Kukreja, R. C., & Das, A. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/4619720 · Cited by 54
Cabrera-Serrano, A. J., Sánchez‐Maldonado, J. M., González‐Olmedo, C., Carretero-Fernández, M., Díaz-Beltrán, L., Gutiérrez‐Bautista, J. F., García‐Verdejo, F. J., Gálvez-Montosa, F., López-López, J. A., García-Martín, P., et al. (2025) · Antioxidants · doi:10.3390/antiox14030264 · Cited by 56
Practical alternatives to chronic caloric restriction for optimizing vascular function with ageing
Martens, C. R., & Seals, D. R. (2016) · The Journal of Physiology · doi:10.1113/jp272348 · Cited by 48
“Adding to this concern is a growing number of adverse side effects associated with rapamycin treatment, leading to advancements in the discovery of safer ‘rapalogs’ as anti-ageing therapies (Lamming et al. 2013).”
BackgroundEmerging Role of mTOR Signaling‐Related miRNAs in Cardiovascular Diseases
Samidurai, A., Kukreja, R. C., & Das, A. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/6141902 · Cited by 51
Rapalogs downmodulate intrinsic immunity and promote cell entry of SARS-CoV-2
Shi, G., Chiramel, A. I., Li, T., Lai, K. K., Kenney, A. D., Zani, A., Eddy, A. C., Majdoul, S., Zhang, L., Dempsey, T., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci160766 · Cited by 54
“Rapalogs, including 79 everolimus (RAD-001), temsirolimus (Torisel, CCI-779), and ridaforolimus (deforolimus, AP80 23573), were developed to decrease the half-life of rapamycin in vivo in order to minimize the 81 systemic immunosuppression caused by rapamycin use, which is associated with increased 82 susceptibility t…”
Panda, P. K., Fahrner, A., Vats, S., Seranova, E., Sharma, V., Chipara, M., Desai, P., Torresi, J., Rosenstock, T., Kumar, D., et al. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00038 · Cited by 50
“Inhibition of mTOR by rapamycin also extended lifespan in yeast, flies and mice (Alvers et al., 2009; Harrison et al., 2009; Bjedov et al., 2010; Lamming et al., 2013).”
BackgroundHejazian, S. M., Hejazian, S. S., Mostafavi, S., Khatibi, S. M. H., Montazersaheb, S., Ardalan, M., Vahed, S. Z., & Barzegari, A. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01968-1 · Cited by 51
“…caloric restriction diets [121] and mimetics [122], proteasome activators [123], autophagy activators [124], antioxidants [125], mTOR inhibitors [126], sirtuin activators [127], and anti-inflammatory agents targeting inflammaging /senoinflammation [128] can be mentioned. ssKU-60,019 induces the…”
ZRF1 is a novel S6 kinase substrate that drives the senescence programme
Barilari, M., Bonfils, G., Treins, C., Koka, V., Villeneuve, D. D., Fabrega, S., & Pende, M. (2017) · The EMBO Journal · doi:10.15252/embj.201694966 · Cited by 55
“Genetic alterations of TORC1 elements affect ageing in yeast, flies, worms and mice (Lamming et al , 2013).”
Lyons, J., Ghazi, P. C., Starchenko, A., Tovaglieri, A., Baldwin, K. R., Poulin, E. J., Gierut, J. J., Genetti, C. A., Yajnik, V., Breault, D. T., et al. (2018) · PLoS Biology · doi:10.1371/journal.pbio.2002417 · Cited by 49
“Rapamycin (or sirolimus) is an inhibitor of the target of rapamycin complex 1 (TORC1) complex, but it should be noted that it can also exert mTOR-independent effects through its ability to bind FK506 binding protein 12 (FKBP12) [18].”
BackgroundAutophagy: An evolutionarily conserved process in the maintenance of stem cells and aging
Vijayakumar, K. A., & Cho, G. (2019) · Cell Biochemistry and Function · doi:10.1002/cbf.3427 · Cited by 50
“It also regulates mTOR through the inhibition of Ras‐related guanosine triphosphate binding.(54) As new pharmacological drugs are discovered in a rapid manner, it could be possible to prolong the aging process.”
BackgroundTang, H., Geng, A., Zhang, T., Wang, C., Jiang, Y., & Mao, Z. (2019) · Protein & Cell · doi:10.1007/s13238-018-0591-y · Cited by 47
Anti-ageing interventions for the treatment of cardiovascular disease
Abdellatif, M., Schmid, S., Fuerlinger, A., & Kroemer, G. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae177 · Cited by 52
“110 113 While aspirin, a common cardiovascular drug, failed to attenuate primary cardiovascular events in elderly otherwise healthy women and men, 114 its low doses may be insufficient for autophagy induction, despite posing a high risk of bleeding.”
Wang, G., Chen, L., Qin, S., Zhang, T., Yao, J., Yi, Y., & Deng, L. (2022) · Advances in Nutrition · doi:10.1093/advances/nmac055 · Cited by 47
Li, D., Li, P., Guo, Z., Wang, H., & Pan, W. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.2863 · Cited by 46
“The PI3K/AKT/mTOR signaling pathway plays a key role in cellular growth and survival, which has been implicated in the pathogenesis of a variety of tumors (26-28).”
Aminov, R. I. (2013) · Frontiers in Microbiology · doi:10.3389/fmicb.2013.00241 · Cited by 48
“#3 development of safer derivatives, termed rapalogs (Lamming et al., 2013).”
Parkhitko, A. A., Favorova, O. O., Khabibullin, D., Anisimov, V. N., & Henske, E. P. (2014) · Biochemistry (Moscow) · doi:10.1134/s0006297914020023 · Cited by 48
Unveiling the impact of aging on BBB and Alzheimer's disease: Factors and therapeutic implications
Nelson, V. K., Jha, N. K., Nuli, M. V., Gupta, S. K., Kanna, S., Gahtani, R. M., Hani, U., Singh, A. K., Abomughaid, M. M., Abomughayedh, A. M., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102224 · Cited by 48
Dual mTOR inhibitor MLN0128 suppresses Merkel cell carcinoma (MCC) xenograft tumor growth
Kannan, A., Lin, Z., Shao, Q., Zhao, S., Fang, B., Moreno, M. A., Vural, E. A., Stack, B. C., Suen, J. Y., Kannan, K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5878 · Cited by 46
Saha, A., Blando, J. M., Tremmel, L., & DiGiovanni, J. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-15-0014 · Cited by 46
“Rapamycin (RAPA) is a macrolide used clinically as an immunosuppressant in organ transplant patients and to treat autoimmune disorders (22).”
BackgroundDietary restriction and the pursuit of effective mimetics
Selman, C. (2014) · Proceedings of The Nutrition Society · doi:10.1017/s0029665113003832 · Cited by 51
Recent Progress in Metabolic Signaling Pathways Regulating Aging and Life Span
Newgard, C. B., & Pessin, J. E. (2014) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glu058 · Cited by 43
“It displays longevity properties in several genetic systems including Saccharomyces cerevisiae, Drosophila Melanogaster, Caenorhabditis elegans, and mice (2).”
BackgroundMHY1485 activates mTOR and protects osteoblasts from dexamethasone
Zhao, S., Chen, C., Wang, S., Ji, F., & Xie, Y. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.10.104 · Cited by 45
Wu, Y., Warner, J. L., Wang, L., Jiang, M., Xu, J., Chen, Q., Nian, H., Dai, Q., Du, X., Yang, P., et al. (2019) · JCO Clinical Cancer Informatics · doi:10.1200/cci.19.00001 · Cited by 42
“We identified 64 ongoing or completed clinical trials studying metformin alone or in combination, whose anticancer effect could be related to mammalian target of rapamycin inhibition.(35,36) Ongoing cancer trials also are evaluating statins for cancer treatment (eg, a trial to assess the efficacy of simvastatin and ca…”
BackgroundDong, L., Wu, J., Li, A., Bi, W., Liu, T., Cao, L., Liu, Y., & Liu, A. (2016) · International Journal of COPD · doi:10.2147/copd.s107396 · Cited by 47
“Activation of the mTOR pathway may play an important role in multimorbidity, and so inhibition of this pathway may offer a good future therapeutic opportunity.(7) In the People’s Republic of China, many traditional Chinese medicines modalities are regularly used in the treatment of patients with COPD.”
BackgroundOveractive mTOR signaling leads to endometrial hyperplasia in aged women and mice
Bajwa, P., Nielsen, S., Lombard, J. M., Rassam, L., Nahar, P., Rueda, B. R., Wilkinson, J. E., Miller, R. A., & Tanwar, P. S. (2016) · Oncotarget · doi:10.18632/oncotarget.13919 · Cited by 43
“Studies from various independent groups have confirmed that pharmacological or genetic suppression of mTOR signaling extends lifespan and healthspan in yeast, worms, flies, and rodents [12, 29, 30].”
BackgroundA natural product solution to aging and aging-associated diseases
Yang, C., Zhang, W., Dong, X., Fu, C., Yuan, J., Xu, M., Liang, Z. C., Qiu, C., & Xu, C. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107673 · Cited by 45
Metadata
- Authors
- Lamming, D. W., Ye, L., Sabatini, D. M., & Baur, J. A.
- Affiliations
- Howard Hughes Medical Institute (US)
- University of Pennsylvania (US)
- Broad Institute (US)
- Corresponding author
- Baur, Joseph A.
- Venue
- Journal of Clinical Investigation
- Published
- 2013-03-01
- Volume
- 123
- Issue
- 3
- Pages
- 980-989
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3582126
- OpenAlex
- W2129902630
- Cited by
- 531
- References
- 133
- Citations by year
- 2026: 18 · 2025: 32 · 2024: 42 · 2023: 37 · 2022: 41 · 2021: 25 · 2020: 28 · 2019: 44 · 2018: 46 · 2017: 38 · 2016: 57 · 2015: 61 · 2014: 46 · 2013: 16
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- Ellison Medical Foundation
- American Federation for Aging Research
- American Heart Association
- Charles A. King Trust
- Starr Foundation
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- National Institutes of Health
- National Institute on Aging (K99AG041765)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Autophagy in Disease and Therapy
- Keywords
- rapamycin, rapalogs, mTOR inhibitors, anti-aging therapeutics, longevity, lifespan extension, mTOR signaling, genetically heterogeneous mice, adverse drug reactions
- MeSH terms
- Aging, Animals, Anti-Inflammatory Agents, Antineoplastic Agents, Autophagy, Humans, Metformin, Neoplasms, Stem Cells, Sirolimus, TOR Serine-Threonine Kinases, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.